Pozytywnie wpywa te na metabolizm, jednak ten mechanizm nie jest do koca odkryty i opisany
Post-marketing surveillance has reported cases of acute pancreatitis, and the FDA has added a warning to labeling.[6] However, the absolute risk remains low, and large observational studies have not confirmed a statistically significant increase in pancreatitis compared to other diabetes medications
Acknowledgments Destinee Elliott and Francesca Veon contributed equally to the work and should be considered co-first authors
Hamilton Health Sciences Corporation
For the Bridge, its weight management paired with a qualifying BMI: 35 or higher on its own, or a lower BMI (30+ or 27+) combined with a specific condition like a heart, kidney, or blood pressure issue, pre-diabetes, or a history of heart attack or stroke